Network pharmacology showed that 251 luteolin against osteosarcoma targets and 8 hub targets including AKT1, ALB, CASP3, IL6, JUN, STAT3, TNF, and VEGFA (Huang et al., 2023). This evidence concerns the gene ALB and osteosarcoma.